Lantheus shares fell 25% post-Q1 2025 report due to disappointing EPS guidance and not meet analysts' expectations. Click ...

The company had also said last month that Paul Stoffels, a pharma legend who took on the CEO role in 2022 in a bid to ...

Ascendis, Ascendis Pharma, the Ascendis Pharma logo, the company logo, TransCon, SKYTROFA ®, and YORVIPATH ® are trademarks owned by the Ascendis Pharma group.

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Visit a quote page and your recently viewed tickers will be displayed here. Cost of Goods Sold (COGS) incl. D&A Cost of Goods Sold (COGS) incl. D&A ...

COPENHAGEN, Denmark, May 01, 2025 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced financial results for the first quarter ended March 31, 2025, and provided a business update.

COPENHAGEN, Denmark, May 01, 2025 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced financial results for the first quarter ended March 31, 2025, and provided a business update.

Lantheus Holdings announced clinical success with its MK-6240 PET radiodiagnostic, showing promise in Alzheimer’s detection, and plans an NDA submission to the FDA. Over the last quarter ...

Silo Pharma’s SP-26 met all preclinical endpoints and aims to qualify for the FDA’s streamlined 505(b)(2) pathway. Today's manic market swings are creating the perfect setup for Matt’s next ...

Along with the proliferation of AI companies has come a proliferation of AI company logos. The fascinating thing, highlighted by several publications, is that many of these logos look near-identical.